These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

592 related items for PubMed ID: 31829288

  • 21. Gallium-68-prostate-specific membrane antigen (68 Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer.
    van Leeuwen PJ, Donswijk M, Nandurkar R, Stricker P, Ho B, Heijmink S, Wit EMK, Tillier C, van Muilenkom E, Nguyen Q, van der Poel HG, Emmett L.
    BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
    [Abstract] [Full Text] [Related]

  • 22. Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer.
    Zhang Q, Zang S, Zhang C, Fu Y, Lv X, Zhang Q, Deng Y, Zhang C, Luo R, Zhao X, Wang W, Wang F, Guo H.
    J Transl Med; 2017 Nov 07; 15(1):230. PubMed ID: 29115970
    [Abstract] [Full Text] [Related]

  • 23. 68Ga-PSMA PET/CT compared with MRI/CT and diffusion-weighted MRI for primary lymph node staging prior to definitive radiotherapy in prostate cancer: a prospective diagnostic test accuracy study.
    Petersen LJ, Nielsen JB, Langkilde NC, Petersen A, Afshar-Oromieh A, De Souza NM, De Paepe K, Fisker RV, Arp DT, Carl J, Haberkorn U, Zacho HD.
    World J Urol; 2020 Apr 07; 38(4):939-948. PubMed ID: 31190153
    [Abstract] [Full Text] [Related]

  • 24. 68Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer.
    Klingenberg S, Jochumsen MR, Ulhøi BP, Fredsøe J, Sørensen KD, Borre M, Bouchelouche K.
    J Nucl Med; 2021 Feb 07; 62(2):214-220. PubMed ID: 32444374
    [Abstract] [Full Text] [Related]

  • 25. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.
    Budäus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, Graefen M, Steuber T, Rosenbaum C.
    Eur Urol; 2016 Mar 07; 69(3):393-6. PubMed ID: 26116958
    [Abstract] [Full Text] [Related]

  • 26. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
    Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, Doherty A, Gschwend JE, Schwaiger M, Eiber M.
    J Nucl Med; 2016 Nov 07; 57(11):1713-1719. PubMed ID: 27261524
    [Abstract] [Full Text] [Related]

  • 27. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.
    Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kübler H, Beer AJ, Schwaiger M, Eiber M.
    J Urol; 2016 May 07; 195(5):1436-1443. PubMed ID: 26682756
    [Abstract] [Full Text] [Related]

  • 28. Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology.
    Yaxley JW, Raveenthiran S, Nouhaud FX, Samartunga H, Yaxley AJ, Coughlin G, Delahunt B, Egevad L, McEwan L, Wong D.
    J Urol; 2019 Apr 07; 201(4):815-820. PubMed ID: 30672842
    [Abstract] [Full Text] [Related]

  • 29. Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy.
    Abufaraj M, Grubmüller B, Zeitlinger M, Kramer G, Seitz C, Haitel A, Baltzer P, Hacker M, Wadsak W, Pfaff S, Wiatr T, Mitterhauser M, Shariat SF, Hartenbach M.
    Eur J Nucl Med Mol Imaging; 2019 Sep 07; 46(10):2169-2177. PubMed ID: 31254037
    [Abstract] [Full Text] [Related]

  • 30. Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer.
    Gondoputro W, Scheltema MJ, Blazevski A, Doan P, Thompson JE, Amin A, Geboers B, Agrawal S, Siriwardana A, Van Leeuwen PJ, van Oosterom MN, Van Leeuwen FWB, Emmett L, Stricker PD.
    J Nucl Med; 2022 Nov 07; 63(11):1659-1664. PubMed ID: 35241483
    [Abstract] [Full Text] [Related]

  • 31. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS, Fendler WP, Buchner A, Stief C, Rogowski P, Niyazi M, Eze C, Li M, Bartenstein P, Belka C, Ganswindt U.
    Radiat Oncol; 2017 Nov 10; 12(1):176. PubMed ID: 29126446
    [Abstract] [Full Text] [Related]

  • 32. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography.
    Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, Lotz J, Schildhaus HU, Trojan L, Sahlmann CO.
    Prostate; 2015 Dec 10; 75(16):1934-40. PubMed ID: 26356236
    [Abstract] [Full Text] [Related]

  • 33. Comparison of 68 Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer.
    Walacides D, Meier A, Knöchelmann AC, Meinecke D, Derlin T, Bengel FM, Ross TL, Wester HJ, Derlin K, Kuczyk MA, von Klot CAJ, Christiansen H, Henkenberens C.
    Strahlenther Onkol; 2019 May 10; 195(5):420-429. PubMed ID: 30610354
    [Abstract] [Full Text] [Related]

  • 34. 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer.
    Kopp D, Kopp J, Bernhardt E, Manka L, Beck A, Gerullis H, Karakiewicz PI, Salomon G, Wiggermann P, Hammerer P, Schiffmann J.
    Urol Int; 2022 May 10; 106(1):56-62. PubMed ID: 33965965
    [Abstract] [Full Text] [Related]

  • 35. The Role of 68GA-PSMA PET/CT Scan In Patients with Prostate Adenocarcinoma who Underwent Radical Prostatectomy.
    Gultekin MH, Demirci E, Turegun FA, Kabasakal L, Sahin OE, Ocak M, Onal B, Erozenci A.
    Urol J; 2020 Dec 09; 18(1):58-65. PubMed ID: 33349912
    [Abstract] [Full Text] [Related]

  • 36. Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer.
    Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, Yaxley AJ, Gianduzzo T, Kua B, McEwan L, Wong D.
    BJU Int; 2019 Sep 09; 124(3):401-407. PubMed ID: 31141284
    [Abstract] [Full Text] [Related]

  • 37. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
    Jilg CA, Drendel V, Rischke HC, Beck T, Vach W, Schaal K, Wetterauer U, Schultze-Seemann W, Meyer PT.
    Theranostics; 2017 Sep 09; 7(6):1770-1780. PubMed ID: 28529650
    [Abstract] [Full Text] [Related]

  • 38. 68 Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer.
    Pfister D, Haidl F, Nestler T, Verburg F, Schmidt M, Wittersheim M, Steib F, Heidenreich A.
    BJU Int; 2020 Dec 09; 126(6):679-683. PubMed ID: 32531840
    [Abstract] [Full Text] [Related]

  • 39. Prostate-Specific Membrane Antigen PET/CT Combined with Sentinel Node Biopsy for Primary Lymph Node Staging in Prostate Cancer.
    Hinsenveld FJ, Wit EMK, van Leeuwen PJ, Brouwer OR, Donswijk ML, Tillier CN, Vegt E, van Muilekom E, van Oosterom MN, van Leeuwen FWB, van der Poel HG.
    J Nucl Med; 2020 Apr 09; 61(4):540-545. PubMed ID: 31562222
    [Abstract] [Full Text] [Related]

  • 40. Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection.
    Dekalo S, Kuten J, Mintz I, Fahoum I, Gitstein G, Keizman D, Sarid D, Matzkin H, Mabjeesh NJ, Beri A, Even-Sapir E, Yossepowitch O, Mano R.
    Prostate Cancer Prostatic Dis; 2021 Sep 09; 24(3):910-916. PubMed ID: 33790418
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.